https://www.selleckchem.com/pr....oducts/rhapontigenin
We observed complications such as stroke (18.2%), sepsis (63.6%), massive gastrointestinal bleed (45.5%), and heparin-induced thrombocytopenia (54.5%). These patients received on average 85 units of blood products. Survival was 82% at 30 days and 72% at 180 days. Six of the patients were successfully weaned from the THPD devices and 1 patient required venovenous extracorporeal life support. This real-world experience, despite high morbidity, continues to suggest benefits of THPD for patients with severe acute RV failure. This real
Like
Comment
Share
